| ACE2 | angiotensin converting enzyme 2 |
| ADA | anti-drug antibodies |
| Ang2 | angiopoietin 2 |
| CDR | complementarity determining region |
| DAF | dual action Fab |
| DMS | deep mutational scanning |
| ELISA | enzyme-linked immunosorbent assay |
| Fab | antigen-binding fragments |
| HCDR | heavy chain complementarity-determining region |
| HDR | homology-directed repair |
| HLA | human leukocyte antigen |
| IgG1 | immunoglobulin G1 |
| mAbs | monoclonal antibodies |
| MHC | major histocompatibility complex |
| PALs | programmed allelic series |
| PCR | polymerase chain reaction |
| PD-1 | programmed cell death protein-1 |
| RBD | receptor binding domain |
| scFv | single-chain variable fragments |
| SUNi | scalable and uniform nicking mutagenesis |
| TCR | T-cell receptor |
| TROP2 | trophoblast cell surface antigen 2 |
| TNF | tumor necrosis factor |
| TP53 | tumor protein p53 |
| PBMC | peripheral blood mononuclear cell |
| PTEN | phosphatase and tensin homolog |
| VEGF | vascular endothelial growth factor |
| VUS | variants of uncertain significance |